Adverse effects of GLP-1 receptor agonists: difference between revisions
Diff·revision 21 → 22·11:46, 26 Mar 2025
Difference between revision 21 and revision 22 of Adverse effects of GLP-1 receptor agonists. 5 lines changed; the page grew by 602 bytes.
| Revision 21 — 15:21, 6 Mar 2025 CostPerMgCory (talk) clarify that the effect resolved on discontinuation in the cited series 4,695 bytes ±0 | Revision 22 — 11:46, 26 Mar 2025 SarcopeniaSefa (talk) expand §Body composition and other effects 5,297 bytes +602 | ||
|---|---|---|---|
| 36 | A signal for non-arteritic anterior ischaemic optic neuropathy has been reported in observational data and remains under evaluation; observational designs cannot exclude confounding by indication.{{r|nauck2016}} | 36 | A signal for non-arteritic anterior ischaemic optic neuropathy has been reported in observational data and remains under evaluation; observational designs cannot exclude confounding by indication.{{r|nauck2016}} |
| 37 | 37 | ||
| + | 38 | == Body composition and other effects == | |
| + | 39 | Loss of lean mass accompanies loss of fat mass, in a proportion broadly comparable with that seen in other forms of substantial caloric restriction. Whether the proportion differs from diet-induced loss is disputed and the trials were not designed to settle it. See [[Sarcopenia]] and [[Lean mass preservation]].{{r|wilding2021}} | |
| + | 40 | ||
| + | 41 | A resting heart-rate increase of two to four beats per minute is reported across the class, attributed to direct sinoatrial action. No adverse outcome has been associated with it in the completed outcome trials.{{r|drucker2018}} | |
| + | 42 | ||
| 38 | == References == | 43 | == References == |
| 39 | {{reflist}} | 44 | {{reflist}} |